STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2001-05-01
Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating
patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways
to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of
leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
Completed
National Cancer Institute (NCI)
Phase 3
2002-10-01
This phase II trial is studying how well combination chemotherapy with or without donor
peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia.
Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the
growth of cancer cells. It also helps stop the patient's immune system from rejecting the
donor's stem cells. When the healthy stem cells from a donor are infused into the patient
they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,
and platelets.
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
Completed
National Cancer Institute (NCI)
Phase 2
2001-09-01
This phase II trial is studying how well imatinib mesylate works in treating patients with
gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate
may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Completed
National Cancer Institute (NCI)
Phase 1
2001-08-01
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop
growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating
patients who have advanced cancer and liver dysfunction
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
